. Author manuscript; available in PMC: 2016 Dec 6.

Published in final edited form as: Pediatr Blood Cancer. 2012 Sep 7;60(3):371–376. doi: 10.1002/pbc.24289

TABLE II.

Best Response Of 24 IRSG Patients With Localized Orbital Rhabdomyosarcoma, Undifferentiated Sarcoma, Or Soft-tissue Sarcoma Not Otherwise Specified, Who Later Relapsed: Salvage Treatment And Survival^*

Patient Number	Best Response	RT (Gray) Prior to Relapse; Evaluation	Sites of Relapse	Time to Relapse in Years	Salvage Therapy	Years After 1° Relapse; + = Alive
1	CR	50.4; WPG	[1]: L parietal brain met., anaplastic ERMS	2.62	~90% tumor removal, no other data	Died due to tumor, 1.79
1	CR	50.4; WPG	[2]: local recurrence	0.38 after [1]		Died due to tumor, 1.79
2	Inc.Dis.	45, WPG	Local	0.613	Exenteration; E, I	8.41 +
3	Inc.Dis.	45.0; WPG	Local	0.210	V, C, D	12.8+
4	PR	48.6; WPG	Local	1.11	C, D, E, P; gross total excision of tumor	8.12+
5	PR	50.4; WPG	Local	1.69	E, I x2; enucleation; D, DTIC x6, Exent.	6.87+
6	PR	45; WPG	Local	1.31	V,C,D,E,P; Exent.; RT	17.0+
7	PR	54.2; rate too slow	Local	0.985	C, D, E, P; Exent.; brachy. RT for microresidual tumor	11.1+
8	CR	45; WPG	Local, extended to cavernous sinus	2.30	Enucleation; D, E, I, P	0.043+
9	Inc.Dis.	0; MPD	Local; no chemo after day 22	0.057	E, I; RT	7.58+
10	CR	41.4; WPG	Local	7.05	Exent.; no other data	3.37+
11	CR	41.4; volume too large	Local	1.08	D, E, I, P	7.49+
12	CR	45, WPG	[1] Local	[1] 1.5	[1] D, I	13.3+
12	CR	45, WPG	[2] L parotid mucoepithelial carcinoma: SMN	[2] 6.0 after [1]	[2] No information	13.3+
13	CR	41.4; WPG	Local	1.57	Exent.; V, C, D	6.48+
14	CR	50.4; WPG	Local	0.785	E, I	0.679+
15	CR	50.4; WPG	Local, extended to maxillary antrum	6.43	E, I; followed by V, A, C	0.846+
16	PR	45; WPG	Local	1.59	Exent.; V, C, D, E, I	10.2+
17	CR	0; MPD	[1] Local	1.69	Exent., V, C, D, I; RT,45 Gray	Died due to tumor, 2.49
17	CR	0; MPD	[2] Local	3.89	Taxol	Died due to tumor, 2.49
18	PR	41.4; MPD, volume low	Local,	0.914	C, D, E, I; RT	13.0+
19	CR	35.7; dose low	Local	5.75	V, D, E; RT, 50 Gy; tumorectomy	8.13+
20	CR	50.4; WPG	Local	2.03	Enucleation; P; no other data	6.13+
21	CR	41.4; WPG	Local	1.84	Biopsy pos.; no other data	5.84+
22	CR	50.6; HF-RT dose too low	R Parotid, with 1 pos., 2 neg. node biopsies	2.39	No data	5.74+
23	NR	0, MPD; sibling with cerebral palsy at home	Local, multiple times; invaded frontal lobe	1.29	Exenteration, RT; later, cystic brain necrosis	6.71+
24	CR	41.4; WPG	Local	1.14	E, I; Exent.; D, V	5.03+

Abbreviations: See Table 1; CR, complete response, PR, partial response; Inc.Dis., increasing disease (local progression); NR, no response; WPG, within protocol guidelines; MPD, major protocol deviation; D, doxorubicin; DTIC, dimethyl triazeno imidazole carboxamide (dacarbazine); E, etoposide; P, cisplatin; R, right; L, left; pos., positive (tumor present); neg., negative (tumor not present); Exent., orbital exenteration; SMN, second malignant neoplasm; brachy. RT, brachytherapy; AWD, alive with disease; met., metastasis; 1°, first.